SBTX — Skinbiotherapeutics Income Statement
0.000.00%
Last trade - 00:00- £60.81m
- £60.60m
- £1.21m
Annual income statement for Skinbiotherapeutics, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.075 | 0.132 | 1.21 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 0.045 | 0.085 | 0.683 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.62 | 1.5 | 3.06 | 3.13 | 4.11 |
| Operating Profit | -1.62 | -1.5 | -2.98 | -3 | -2.91 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.62 | -1.5 | -2.99 | -3.01 | -2.95 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.5 | -1.43 | -2.79 | -2.84 | -2.88 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.5 | -1.43 | -2.79 | -2.84 | -2.88 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.5 | -1.43 | -2.79 | -2.84 | -2.88 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.012 | -0.01 | -0.018 | -0.017 | -0.015 |